OvaScience to Present at the Wedbush PacGrow Healthcare Conference
August 05 2015 - 8:30AM
Business Wire
OvaScienceSM (NASDAQ: OVAS), a global fertility company focused
on the discovery, development and commercialization of new
treatment options, announced today that Company management will
present at the 2015 Wedbush PacGrow Healthcare Conference on
Tuesday, August 11, 2015 at 1:55 pm ET at Le Parker Meridien in New
York City.
A live audio webcast of the presentation can be accessed by
visiting the Investors section of the Company’s website at
www.ovascience.com. A replay of the webcast will be archived on the
OvaScience website for two weeks following the presentation.
About OvaScienceOvaScience (NASDAQ: OVAS) is a global
fertility company dedicated to improving treatment options for
women around the world. OvaScience is discovering, developing and
commercializing new fertility treatments because we believe women
deserve more options. Each OvaScience treatment is based on the
Company’s proprietary technology platform that leverages the
breakthrough discovery of egg precursor (EggPCSM) cells – immature
egg cells found inside the protective ovarian lining. The
AUGMENTSM treatment, a fertility option specifically designed
to improve egg health, is available in certain IVF clinics in
select international regions outside of the United States.
OvaScience is developing the OvaPrimeSM treatment, which could
increase a woman’s egg reserve, and the OvaTureSM treatment, a
potential next-generation IVF treatment that could help a woman
produce healthy, young, fertilizable eggs without hormone
injections. For more information, please
visit www.ovascience.com and connect with us
on Twitter and Facebook.
Forward-Looking StatementsThis press release includes
forward-looking statements about the Company’s plans for the
AUGMENT treatment and two fertility treatments in development.
Actual results may differ materially from those indicated by these
forward-looking statements as a result of various important
factors, including risks related to: the possibility that
international IVF clinics that we work with may determine not to
begin or continue providing the AUGMENT treatment for commercial or
other reasons; our expectation that the AUGMENT treatment and
OvaPrime treatment meet the requirements of a class of products
exempt from premarket review and approval under applicable
regulations in those countries where we have launched or plan to
introduce the AUGMENT treatment and plan to introduce the OvaPrime
treatment; the commercial ramp up of the AUGMENT treatment, which
we expect will depend upon the successful transition of ACE clinics
to commercial operations, the addition of new ACE clinics, and the
results from ACE clinic experience as they become available; the
science underlying our treatment and treatments in development
(including the AUGMENT, OvaPrime and OvaTure treatments), which is
unproven; our ability to obtain regulatory approval where necessary
for our potential treatments; our ability to develop our potential
treatments, including the OvaPrime and OvaTure treatments, on the
timelines we expect, if at all; our ability to commercialize the
AUGMENT treatment and our potential treatments, including the
OvaPrime treatment, on the timelines we expect, if at all; as well
as those risks more fully discussed in the “Risk Factors” section
of our most recently filed Quarterly Report on Form 10-Q and/or
Annual Report on Form 10-K. The forward-looking statements
contained in this press release reflect our current views with
respect to future events. We anticipate that subsequent events and
developments will cause our views to change. However, while we may
elect to update these forward-looking statements in the future, we
specifically disclaim any obligation to do so. These
forward-looking statements should not be relied upon as
representing our view as of any date subsequent to the date
hereof.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150805005357/en/
OvaScienceInvestorsTheresa McNeely, 617-299-7356EVP,
Chief Communications
Officertmcneely@ovascience.comorMediaCara Mayfield,
617-714-9638Director, Corporate
Communicationscmayfield@ovascience.com
Ovascience Inc. (delisted) (NASDAQ:OVAS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ovascience Inc. (delisted) (NASDAQ:OVAS)
Historical Stock Chart
From Apr 2023 to Apr 2024